Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neuroscience. Pfizer expects to grow Biohaven's oral CGRP franchise…
William Blair analysts wrote the acquisition is a good deal for both Pfizer and Biohaven, viewing it as clear validation of Nurtec ODT's leadership position in…
Nurtec ODT/Vydura full-year 2025 revenue of $1,424 million (2% of total revenue), confirming continued CGRP franchise growth under Pfizer ownership.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer acquired Biohaven Pharmaceuticals for approximately $11.6 billion ($148.50 per share in cash), gaining Nurtec ODT (rimegepant), a dual-action CGRP receptor antagonist approved for both acute treatment and prevention of migraine. Prior to closing, Biohaven spun off its non-CGRP pipeline into a new public entity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Biohaven Pharmaceutical Holding Company Ltd. (this deal) | 2022 | $11.6B | 69 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Neurology deals